Insider-Owned ASX Growth Companies To Watch In July 2024

The Australian market has shown robust growth, climbing 1.4% in the last week and achieving a 10% increase over the past year, with earnings projected to grow by 13% annually. In this environment, growth companies with high insider ownership can be particularly compelling, as they often indicate a strong alignment between company management and shareholder interests.

Top 10 Growth Companies With High Insider Ownership In Australia

Name	Insider Ownership	Earnings Growth
Cettire (ASX:CTT)	28.7%	26.7%
Clinuvel Pharmaceuticals (ASX:CUV)	13.6%	26.7%
Acrux (ASX:ACR)	14.6%	115.3%
Biome Australia (ASX:BIO)	34.5%	114.4%
Liontown Resources (ASX:LTR)	16.4%	59.4%
Ora Banda Mining (ASX:OBM)	10.2%	94.3%
Hillgrove Resources (ASX:HGO)	10.4%	45.4%
Change Financial (ASX:CCA)	26.6%	76.4%
Plenti Group (ASX:PLT)	12.8%	106.4%
DUG Technology (ASX:DUG)	28.1%	43.2%

Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's explore several standout options from the results in the screener.

Emerald Resources (ASX:EMR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Emerald Resources NL is a company focused on the exploration and development of mineral reserves in Cambodia and Australia, with a market capitalization of approximately A$2.53 billion.

Operations: The company generates revenue primarily from mine operations, totaling approximately A$339.32 million.

Insider Ownership: 18.5%

Emerald Resources, an Australian growth company, shows a promising outlook with significant earnings and revenue growth forecasts above market averages at 23.2% and 18.6% per year respectively. Despite recent shareholder dilution, EMR maintains high insider ownership with no substantial insider selling in the past three months. The projected Return on Equity is also strong at 20.7%, positioning it well for future performance despite some operational challenges.

• Dive into the specifics of Emerald Resources here with our thorough growth forecast report.
• According our valuation report, there's an indication that Emerald Resources' share price might be on the expensive side.

Flight Centre Travel Group (ASX:FLT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Flight Centre Travel Group Limited operates as a travel retailer serving both leisure and corporate sectors across Australia, New Zealand, the Americas, Europe, the Middle East, Africa, and Asia with a market capitalization of A$4.71 billion.

Operations: The company generates revenue primarily through its leisure and corporate travel segments, with A$1.28 billion from leisure travel and A$1.06 billion from corporate travel services.

Insider Ownership: 13.3%

Flight Centre Travel Group, positioned in the Australian market, exhibits a robust forecast with its Return on Equity expected to reach 21.8% in three years. While its revenue growth at 9.7% per year is below the high-growth benchmark of 20%, it surpasses the Australian market average of 5.3%. Earnings are anticipated to grow by 18.84% annually, outpacing the market's expectation of 13%. Additionally, FLT trades at a considerable discount, valued at 31% below its estimated fair value, although insider trading activity has been neutral recently.

• Delve into the full analysis future growth report here for a deeper understanding of Flight Centre Travel Group.
• Our valuation report unveils the possibility Flight Centre Travel Group's shares may be trading at a discount.

Mesoblast (ASX:MSB)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited is a biotechnology company focused on developing regenerative medicine products, operating in Australia, the United States, Singapore, and Switzerland, with a market capitalization of approximately A$1.25 billion.

Operations: The company generates revenue primarily from its development of adult stem cell technology platform, totaling A$7.47 million.

Insider Ownership: 22.6%

Mesoblast Limited, an Australian biotech firm, is poised for significant growth with a projected annual revenue increase of 45.5%, notably outpacing the market's average. Despite facing profitability challenges, Mesoblast is expected to become profitable within three years and has shown a commitment to innovation in treatments for severe inflammatory conditions. Recent insider buying trends underscore strong confidence from within, although shareholder dilution over the past year tempers this optimism slightly. The company's recent resubmission of its BLA for Ryoncil highlights its potential in addressing unmet medical needs in pediatric care.

• Navigate through the intricacies of Mesoblast with our comprehensive analyst estimates report here.
• In light of our recent valuation report, it seems possible that Mesoblast is trading behind its estimated value.

Make It Happen

• Discover the full array of 91 Fast Growing ASX Companies With High Insider Ownership right here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com